Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCAPE: Switching Atripla to Eviplera for Neurocognition in HIV
NCT02308332Phase 4Completed
- Start
- Feb 2015
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of emtricitabine + rilpivirine + tenofovir disoproxil fumarate in human immunodeficiency virus type 1 infection (HIV-1) (2 arms). Primary endpoint: Neurocognitive performance as measured by neuropsychological test composite score at 12 weeks. Started Feb 2015; status: completed.
02
Drugs
emtricitabine + rilpivirine + tenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02308332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02308332.